Gastrointestinal Complications in Renal Transplant Recipients: MITOS Study

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2190-2193

  Gil Vernet, S ^a   Amado, A ^b   Ortega, F ^c   Alarcon A ^d   Bernal, G ^e   Capdevila, L ^f   Crespo, J F ^g   Cruzado, J M ^a   De Bonis, E ^h   Esforzado, N ⁱ   Fernandez, A M ^j   Franco, A ^k   Hortal, L ^j   Jimenez C ^l  

^a L'Hospitalet de Llobregat   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d Epidemiologist Res U Son Dureta H   (Spain)

^e Servicio de Hematología H Virgen del Rocio   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g H U de Canarias ^*

^h H Clinic de Barcelona   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^k Hospital University la Paz   (Spain)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; STOMACH PROTECTION;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; SPAIN;

EID: 34548795914     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.07.015     Document Type: Article

References (17)

1. Hariharan S., Johnson C.P., Bresnahan B.A., et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342 (2000) 605
2. Ponticelli C., and Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 18 (2005) 643
3. Sarkio S., Halme L., Kyllonen I., and Salmela K. Severe gastrointestinal complications after 1,515 adult kidney transplantations. Transplant Int 17 (2004) 505
4. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patternson clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
5. Knoll G.A., McDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
6. Helderman J.H., and Goral S. Gastrointestinal Complications of Transplant Immunosuppression. Review. J Am Nephrol 13 (2002) 277
7. Rubin R.H. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppresant- induced gastrointestinal toxicities. Clin Transplant 15 Suppl4 (2001) 11
8. Hardinger K.L., Brennan D.C., Lowel J., and Schnitzer M.A. Long-term outcome of gastrointestinal complications in renal transplant patients treated with MMF mofetil. Clin Transplant Int 17 (2004) 609
9. Pirsch J.D., Miller J., Deierhoi M.H., et al. A comparison of FK506 and CsA for immunosuppression after cadaveric renal transplantation. Transplantation 63 (1997) 977
10. Mayer A.D., Dmitrwski J., Squifflet J.-P., et al. Multicenter randomized trail comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus Multicenter Renal Study Group. Transplantation 64 (1997) 436
11. Altiparmak M.R., Trablus S., Pamuk O.N., et al. Diarrhoea following renal transplantation. Clin transplant 16 (2002) 212
12. Tierce J.C., Porterfield-Baxa J., Petrilla A.A., et al. Impact of mycophenolate mofetil(MMF) related gastrointestinal complications and MMF dose alterations on transplant outcomes and health care costs in renal transplant recipients. Clin Transplant 19 (2005) 779
13. Bunnapradis S., Lentine K.L., Burroughs T.E., et al. Mycophenolate Mofetil dose reduction and discontinuation after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
14. Massari P, Duro-García V, Giron F, et al: Safety assesment of the conversión from mycophenolate mofetil to enteric coated mycophenolate sodiun in stable renal transpalnt recipients.
15. Nasah B., Suwelack B., Ivens K., et al. Conversion to enteric coated mycophenolate sodium from various dose of mycophenolate mofetil:results of a prospective international multicenter trial in maintenace renal transplant patients receiving cyclosporine. Transplant Proc 38 (2006) 2856
16. Budde K., Glander P., Diekmann F., et al. Review of immunosuppresant enteric coated mycophenolate sodium. Expert Opin Pharmacother 5 (2004) 1333
17. Pietruck F., Abbud-Filho M., Vathsala A., et al. Conversion from Mycophenolate mofetil to enteric coated mycophenolate sodium in stable maintenance renal transplan patients: pooled results from three international multicenter studies. Transplant Proc 39 (2007) 103